Emerging Biomarkers for Immunotherapy in Glioblastoma

SIMPLE SUMMARY: Immunotherapy has shown clinical benefits in several solid cancers; still, glioblastoma remains very challenging to treat. Glioblastoma is the most frequent brain cancer and displays great heterogeneity. The standard of care has remained the same for over fifteen years, and to overco...

Descripción completa

Detalles Bibliográficos
Autores principales: Mensali, Nadia, Inderberg, Else Marit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024739/
https://www.ncbi.nlm.nih.gov/pubmed/35454848
http://dx.doi.org/10.3390/cancers14081940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024739/
https://www.ncbi.nlm.nih.gov/pubmed/35454848
http://dx.doi.org/10.3390/cancers14081940

Ejemplares similares